Blood Vessels

NCI awards funding for tumor-targeted siRNA therapeutic

Published in Medical Letter on the CDC and FDA, June 20th, 2004

Intradigm Corp. announced that it has been awarded a phase I small business innovation research grant by the U.S. National Cancer Institute (NCI) to support development of the company's lead cancer siRNA therapeutic product.

Dr. Puthupparampil Scaria, vice president of synthetic vectors at Intradigm, is the principle investigator of this grant, titled "Targeted delivery of siRNA to inhibit tumor growth." This lead product conveys two levels of targeting - tissue-targeted siRNA that inhibits the VEGF pathway selectively at new blood vessels within tumors.

The VEGF pathway is a key for the process used by tumors to generate the new blood vessels they...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry